Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dzala LLC holds a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This single action is assigned to 1 distinct art unit, indicating that the company's current intellectual property prosecution is focused on a specific technical area within the pharmaceutical field.
The prosecution involves 1 distinct examiner, ALAWADI, SARAH. As the busiest examiner for the portfolio, ALAWADI, SARAH is currently managing 1 busiest examiner pending office action. This 1 pending action represents the entire active workload for Dzala LLC at the patent office, suggesting a concentrated effort on a single patent application.
Practitioners can focus their strategy entirely on the 1 pending office action and the examination style of ALAWADI, SARAH. Because the portfolio is limited to 1 distinct examiner and 1 distinct art unit, the administrative complexity is low. The firm can dedicate its resources to navigating the specific requirements of the Biotechnology & Pharmaceuticals sector as interpreted by this single examiner to move the 1 pending office action toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAWADI, SARAH | 1 | 37.5% | +38.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033383 | Novel compositions for neutralizing toxic effects of hydrogen peroxide in living cells or tissues | ALAWADI, SARAH | 15d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033383 | Novel compositions for neutralizing toxic effects of hydrogen peroxide in living cells or tissues | ALAWADI, SARAH | 15d |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033383 | Novel compositions for neutralizing toxic effects of hydrogen peroxide in living cells or tissues | ALAWADI, SARAH | 1619 | §101§102§103§112 | Non-Final OA | 15d | Pending | Apr 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial